CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

NCT07366112 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

158

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor-Positive Breast Cancer
High-risk Breast Cancer
Early-Stage Breast Cancer
HER2-negative Breast Cancer
ctDNA Monitoring

Interventions

DRUG: CDK4/6 inhibitor with endocrine therapy

Sponsor

Peking University People's Hospital